EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pan-cancer analysis reveals the prognostic and therapeutic relevance of MEX3A with a focus on chromophobe renal cell carcinoma

Shuang Wang, Jiejun Zhang, Mengyu Zheng, Yi Feng, Tao Li

Frontiers in Oncology · 29.04.2026 · 16

DOI: 10.3389/fonc.2026.1802679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 29.04.2026. Verfasst von Shuang Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nursing Department, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

MEX3A is an RNA-binding protein implicated in post-transcriptional regulation; however, its role across cancers, particularly in chromophobe renal cell carcinoma (chRCC), remains unclear.

Methods

We performed a comprehensive pan-cancer analysis using TCGA and related databases to evaluate MEX3A expression, prognostic significance, immune associations, genomic alterations, and drug sensitivity. Functional experiments were conducted in chRCC cell lines.

Results

MEX3A was significantly upregulated in multiple cancers and was associated with poor prognosis. Its expression correlated with immune cell infiltration, immune checkpoint molecules, tumor mutational burden, and microsatellite instability. High MEX3A expression was linked to reduced drug sensitivity. Functional assays confirmed its oncogenic role in chRCC.

Conclusion

MEX3A serves as a potential prognostic biomarker and therapeutic target in chRCC and may play a critical role in tumor progression and immune regulation.

Schlagwörter

Stichwörter der Autor:innen

MEX3AchRCCdrug sensitivitygenomic regulationimmune regulationprognostic biomarker

Autor:innen und Institutionen

  • Nursing Department, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Neurology Department, Yanda Hospital, Langfang, China.
  • Department of Cardiology, Kaifeng Central Hospital, Kaifeng, China.
  • Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China (Harbin Medical University), Ministry of Education, Harbin, China.
  • Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.

Zitieren

APA

Wang, S., Zhang, J., Zheng, M., Feng, Y., & Li, T. (2026). Pan-cancer analysis reveals the prognostic and therapeutic relevance of MEX3A with a focus on chromophobe renal cell carcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1802679

Vancouver

Wang S, Zhang J, Zheng M, Feng Y, Li T. Pan-cancer analysis reveals the prognostic and therapeutic relevance of MEX3A with a focus on chromophobe renal cell carcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1802679

BibTeX
@article{Wang2026,
  author = {Wang, Shuang and Zhang, Jiejun and Zheng, Mengyu and Feng, Yi and Li, Tao},
  title = {Pan-cancer analysis reveals the prognostic and therapeutic relevance of MEX3A with a focus on chromophobe renal cell carcinoma},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1802679}
}
Kostenlos starten →